Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer
Yen‐Ting Lin, Tzu-Hsiu Tsai, Shang‐Gin Wu, Yinan Liu, Chong‐Jen Yu, Jin‐Yuan Shih
Topics & Concepts
OsimertinibT790MMedicineLung cancerOncologyInternal medicineEpidermal growth factor receptorCancerCancer researchGefitinibErlotinibLung Cancer Treatments and MutationsInterstitial Lung Diseases and Idiopathic Pulmonary FibrosisLung Cancer Diagnosis and Treatment